ASH 2020 | ASCT eligibility in myeloma patients aged ≥ 75
Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, discusses a study focusing on the selection of patients eligible for autologous stem cell transplantation (ASCT) in a cohort of multiple myeloma patients aged over 75. In this study, a total of 50 patients were selected for ASCT and only one transplant-related mortality was reported. The progression-free survival rates were found to be the same as in patients under the age of 65. These findings suggest that selection for ASCT eligibility should not be based on age alone, but rather requires individual patient assessment for frailty and presence of comorbidities. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
